Unbiased Analysis of Today's Healthcare Issues
Check out my new paper titled “Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies“. The abstract is below. Purpose: Traditional value assessment frameworks are challenged in comprehensively assessing the societal value new therapies bring to individuals with rare, progressive, genetic, fatal, neuromuscular diseases such as Duchenne muscular dystrophy (DMD). The…
That is the title of my new paper in Annals of the American Thoracic Society with co-authors David Ost, Fabien Maldonado, Jaehong Kim , Moises Marin, Tony Amos, Deanna Hertz, Iftekhar Kalsekar, and Anil Vachani. The abstract is below. Rational: While previous studies have assessed the clinical or economic value of specific technologies, the economic…
That is the title of the podcast episode I was on for AJMC’s Managed Care Cast. We discuss my recently published paper on insurance value in Duchenne’s Muscular Dystrophy (DMD). To learn more about research in DMD, check out AJMC’s DMD compendia page. The full podcast is below.
This is the title of a new paper I have out today at JMCP with co-authors Shanshan Wang, Jaehong Kim, Slaven Sikirica, and Alexander Sandhu with the subtitle “An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes“. The abstract is below: BACKGROUND: Heart failure (HF) is among the leading…
Check out my new publication with co-authors Suhail Thahir, Alexa Klimchak, Ivana Audhya, Lauren Sedita, and John Romley titled “Quantifying the Insurance Value for Rare Diseases: Duchenne Muscular Dystrophy” in AJMC. The abstract is below. Objectives: To quantify the magnitude of an ISPOR novel value element, insurance value, as applied to new treatments for a rare,…
That is the title of my article with Jaehong Kim, Shanshan Wang and Slaven Sikirica in the Journal of Comparative Effectiveness Research. The abstract is below. Aim: To assesses the cost–effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes. Materials & methods: A de novo cost–effectiveness model with a Markov structure was created…
That is the title of my article with Melanie Whittington and Louis Garrison in STAT News. An excerpt is below: The changing landscape of drug pricing policy in the U.S. has implications for the global pace and direction of innovation. Drug policy changes are being influenced by perceptions of the value of novel medicines relative…
That is the title of a paper currently published (well, in pre-prints) at Value in Health. Co-authors include Jaehong Kim, Moises Marin MA, Sangeetha Ramsagar, Mark Lloyd Davies, Kyana Stewart, Iftekhar Kalsekar and Anil Vachani. The abstract is below: ObjectiveTo measure the value of increasing lung cancer screening rates for high-risk individuals and its impact…
That is the title of my new paper published today in Clinical and Applied Thrombosis/Hemostasis with co-authors Denise Clayton, Glorian Yen, Soyon Lee, Lincy Geevarghese, Yulin Shi, Luyang He, Ying Shen, and Anem Waheed. The abstract is below: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder commonly treated with complement inhibitors such as…
That is the title of my new paper out in ClinicoEconomics and Outcomes Research. This work was done with co-authors Kyi-Sin Than, Anmol Kanotra, Kirk W Kerr, Katie N Robinson, Michael C Willey. The abstract is below. Objective: To measure the economic impact of conditionally essential amino acids (CEAA) among patients with operative treatment for fractures.Methods: A…